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Abstract: The identification of noninvasive biomarkers able to detect renal cell carcinoma (RCC) at an
early stage remains an unmet clinical need. The recognition that altered metabolism is a core hallmark
of cancer boosted metabolomic studies focused in the search for cancer biomarkers. The present work
aims to evaluate the performance of the volatile metabolites present in the extracellular medium to
discriminate RCC cell lines with distinct histological subtypes (clear cell and papillary) and metastatic
potential from non-tumorigenic renal cells. Hence, volatile organic compounds (VOCs) and volatile
carbonyl compounds (VCCs) were extracted by headspace solid-phase microextraction (HS-SPME)
and analyzed by gas chromatography–mass spectrometry (GC–MS). Multivariate and univariate
analysis unveiled a panel of metabolites responsible for the separation between groups, mostly
belonging to ketones, alcohols, alkanes and aldehydes classes. Some metabolites were found similarly
altered for all RCC cell lines compared to non-tumorigenic cells, namely 2-ethylhexanol, tetradecane,
formaldehyde, acetone (increased) and cyclohexanone and acetaldehyde (decreased). Furthermore,
significantly altered levels of cyclohexanol, decanal, decane, dodecane and 4-methylbenzaldehyde
were observed in all metastatic RCC cell lines when compared with the non-metastatic ones. Moreover,
some alterations in the volatile composition were also observed between RCC histological subtypes.
Overall, our results demonstrate the potential of volatile profiling for identification of noninvasive
candidate biomarkers for early RCC diagnosis.
Keywords: renal cell carcinoma; cell lines; metabolomics; volatile compounds;
HS-SPME/GC–MS; biomarkers
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1. Introduction
Renal cell carcinoma (RCC) accounts for more than 90% of all kidney malignancies [1] and
represents the second most lethal urological cancer [2]. Comprising a heterogeneous group of tumors,
RCC can be subdivided into several histological subtypes according to distinct clinical and histological
features and different outcomes [3,4]. The main groups include clear cell renal cell carcinoma (ccRCC),
papillary renal cell carcinoma (pRCC) and chromophobe renal cell carcinoma (chRCC), among other
rare types [3]. ccRCC is the most prevalent histological subtype, representing more than 75% of all
RCCs [5], followed by pRCC, which represents 10%–15% of cases [6].
RCC has a favorable prognosis when detected at an early stage [7]. However, this disease prevails
asymptomatically until the advanced stages [8] and no satisfactory biomarkers for clinical management
are currently used [9,10]. Despite the use of imaging techniques, such as the computed tomography
scan, ultrasound exam and/or magnetic resonance, it is indispensable to perform a biopsy of the tumor
to obtain a precise diagnosis [11,12]. Hence, the development of accurate and non-invasive diagnostic
methods based on detection of specific biomarkers in an early stage is of upmost relevance for RCC
prognosis and follow-up [9,10].
The use of metabolomics for investigation of novel biomarkers in oncobiological studies has
been rising over the years [13]. Metabolomics, defined as the study of endogenously produced low
molecular weight compounds, enables the identification of alterations on metabolite levels that reflect
the biological activity of cancer cells [14]. RCC has been considered a metabolic disease [15] due to
several alterations in metabolites associated with energy metabolism, particularly those involved in
pathways for sustaining cell proliferation [10,16]. The majority of RCC metabolomic studies aims to
discriminate RCC patients from controls with diagnostic purposes, but also to investigate the metabolic
deviations associated with the onset of RCC, through the use of mass-spectrometry (MS) and nuclear
magnetic resonance spectroscopy (NMR) [8,10,17–19]. These studies have found increased levels of
several types of carnitines and metabolites from fatty acid metabolism in tissue and urine from RCC
patients compared to control individuals [17]. The levels of carbohydrate-related metabolites as lactate,
pyruvate, glutamate and glucose, among others, have also been found altered in serum/plasma [19],
renal tissue [8,18] and urine from RCC patients [19]. Among all biological matrices used in metabolomic
studies, urine may be considered the preferential matrix for RCC biomarker discovery since it can offer
a non-invasive tool for RCC diagnosis allied with the enormous advantage to be in direct contact with
the kidney. However, urine also reflects the metabolic alterations associated factors not related with
the disease state, usually called confounding factors, such as age, diet, gender and medication, among
others, thus introducing “metabolomic variability” and/or masking valid information [16]. To overcome
this issue, we propose herein a bottom-up metabolomic approach (matrices of increasing complexity)
focused on the investigation of potential RCC biomarkers in in vitro models to be confirmed and
validated in urine from RCC patients in the future.
Volatile organic compounds (VOCs) are end products of cellular metabolism excreted by
cells [20,21] and the analysis of those compounds in the exometabolome can provide the metabolic
signature directly originated from RCC cells. Scientific evidence has demonstrated that the alterations
in the volatile part of exometabolome (VOCs and volatile carbonyl compounds (VCCs) profiles) reflect
the genetic mutations, adaptations and modifications in biochemical pathways of tumor cells [21].
Therefore, these compounds can be used as potential biomarkers for RCC detection and diagnosis.
The use of in vitro models to study the volatile signatures of cancer cells, thus avoiding the bias
introduced by confounding factors, has already been reported by other authors [21–25]. Indeed,
deviations in the levels of VOCs have been proven for prostate [21], lung [22,23], bladder [24] and
breast [25] cancer cells, whereas the dysregulations occurring in the volatile exometabolome profile of
RCC cells are still unexplored. The volatile signature of RCC has only been investigated using more
complex matrices, such as urine, for which significant differences in VOC levels have been found
between patients and control individuals [26,27].
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Hence, this study aimed to investigate, for the first time, the performance of VOCs and VCCs in
discriminating RCC cell lines (769-P, 786-O, Caki-1, Caki-2 and ACHN) from one non-tumorigenic
renal cell line (HK-2). We further investigated which metabolites might discriminate RCC cell lines
according to their histological subtype (ccRCC vs. pRCC) and metastatic potential (metastatic vs.
non-metastatic RCC). Prior to analysis by gas chromatography-mass spectrometry (GC–MS), VOCs
present in the extracellular medium were directly extracted by headspace solid-phase microextraction
(HS-SPME), while VCCs were first derivatized before HS-SPME to enhance the detection of aldehydes
(CHO-) and ketones (CO-) [28]. Knowledge on deviations occurring in the levels of volatiles in RCC
cells may provide new and specific biomarker candidates to be validated in urines from RCC patients
in the future and, therefore, to obtain a powerful tool enabling faster non-invasive RCC diagnosis.
2. Results
In this study, the exometabolome volatile profile of several RCC cell lines (769-P, 786-O, Caki-1,
Caki-2 and ACHN) and one non-tumor renal cell line (HK-2) was analyzed to investigate whether
volatile compounds might be able to discriminate tumorigenic from non-tumorigenic cells. The two
most common histological subtypes, ccRCC and pRCC, at different disease stages were selected for this
study, thus extending our investigation to the metabolic differences that characterize the histological
subtype and tumor stage. The number of peaks detected in the extracellular medium in VOCs and
VCCs analyses were 105 and 111, respectively (Figure S1). A very good reproducibility was achieved
for both analytical methodologies, since all QCs were clustered in the unsupervised analysis (Figure S2).
For VOCs, the principal component analysis (PCA) model including all cell lines and blanks (Figure 1A)
unveiled one main cluster including all cell lines and another cluster of blanks (culture medium in
the same conditions but without cells). For VCCs, three different clusters were observed in PCA
(Figure 1B), namely one including the non-tumor cell line (HK-2) and blanks, a second including the
cancer cell lines, and the last composed only by Caki-2. These results suggested that the RCC cell lines
exhibited a distinct volatile profile when compared with the non-tumor cell line and blanks.Figure 1
A B
Figure 1. Principal component analysis (PCA) scores scatter plots obtained for the headspace solid-phase
microextraction (HS-SPME)/gas chromatography–mass spectrometry (GC–MS) chromatogram data of
(A) volatile organic compounds (VOCs) and (B) volatile carbonyl compounds (VCCs) of culture media
of HK-2 (green, n = 12), 769-P (dark blue, n = 13), 786-O (red, n = 14), Caki-1 (orange, n = 11), Caki-2
(purple, n = 12), ACHN (light blue, n = 12) and blanks (pink, n = 14).
2.1. Volatile Exometabolome Signature of RCC Cell Lines versus the Non-Tumorigenic Cell Line
Pairwise multivariate supervised analysis (PLS-DA) was performed between each RCC cell line
and the non-tumorigenic cell line for both analytical methodologies, VOCs and VCCs (Figure 2A,B,
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respectively). The models showed a very robust discrimination for all comparisons with high predictive
ability (Q2 > 0.5). Figure 2
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Figure 2. Pairwise partial least squares-discriminant analysis (PLS-DA) scores scatter plots obtained for
the HS-SPME/GC–MS chromatogram data of (A) VOCs and (B) VCCs of culture media of each tumor
cell line vs. the non-tumor cell line. (a,f) 769-P (dark blue, n = 13) vs. HK-2 (green, n = 12), (b,g) 786-O
(red, n = 14) vs. HK-2 (green, n = 12), (c,h) Caki-1 (yellow, n = 11) vs. HK-2 (green, n = 12), (d,i) Caki-2
(purple, n = 12) vs. HK-2 (green, n = 12) and (e,j) ACHN (light blue, n = 12) vs. HK-2 (green, n = 12).
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The compounds altered between each tumor cell line versus the non-tumor are shown in Tables 1
and 2. Overall, the compound classes found altered comprised several alcohols, alkanes, alkenes,
aldehydes, benzene derivatives and ketones. Interestingly, a higher number of discriminant metabolites
was found for ccRCC vs. HK-2 (26 compounds; Table 1) when compared with pRCC vs. HK-2 (15
compounds; Table 2). Some alterations were found in common for all ccRCC and pRCC cell lines
compared with HK-2, including increased levels of 2-ethylhexanol, tetradecane, formaldehyde, acetone
and an unknown compound (Un RT 10.18, m/z 58), and the decrease in the levels of acetaldehyde and
cyclohexanone. These results suggest the existence of a common regulatory mechanism in ccRCC and
pRCC cells.
The analysis of the volatile profile of blanks enabled the interpretation of dysregulations occurring
in RCC cells in terms of excretion or consumption of culture medium nutrients. The heatmap depicted
in Figure 3 shows the average peak area of each altered compound in blanks, HK-2, ccRCC and
pRCC cell lines. The hierarchical clustering shown for compounds helps to interpret the patterns
of compound concentrations that changed across different groups. Hence, cyclohexanol, decanal,
2,6-dimethyl-7-octen-2-ol, levomenthol, cyclohexanone, acetaldehyde and acetophenone showed a
trend for lower levels in ccRCC cell lines compared with HK-2 and blanks, indicating the occurrence of
an increased consumption by these cell lines, except for cyclohexanol and decanal in Caki-1 for which
the levels were similar to that of HK-2 and blanks. Tetradecane, 2-ethylhexanol and acetone unveiled a
tendency for higher levels in ccRCC cell lines compared with HK-2 and blanks, suggesting an increased
excretion of those compounds by ccRCC cell lines. 2-Ethoxy-2-methylpropane, 2,4-dimethyl-1-heptene
and 4-methylbenzaldehyde were consumed by all cell lines but at a lower extent in 769-P and 786-O
compared with HK-2 (Table 1). Benzaldehyde and formaldehyde showed a tendency for consumption in
ccRCC and HK-2 cell lines, but a different profile was observed for both metabolites with formaldehyde
showing increased levels in ccRCC lines in relation to HK-2, while for benzaldehyde only 786-O
unveiled statistically significant results when compared with HK-2 (Table 1). Decane, 3-carene,
3-methylbenzaldehyde, styrene, xylene and ethylbenzene showed a distinct profile in HK-2 and Caki-1,
which seem to consume higher levels of those compounds (Table 1 and Figure 3). Regarding the
pRCC cell lines, Caki-2 and ACHN showed a larger excretion of 2-ethylhexanol, tetradecane and
acetone, whereas only Caki-2 unveiled a higher excretion of cyclohexanol (Table 2 and Figure 3).
3-Methylbenzaldehyde and 4-methylbenzaldehyde showed a different variation pattern for Caki-2 and
ACHN (Figure 3). Formaldehyde was consumed by pRCC and HK-2 cell lines but at a lower extent for
Caki-2 and ACHN. 2-Pentadecanone, acetophenone and cyclohexanone exhibited a distinct profile in
Caki-2 when compared with HK-2, ACHN and blanks, characterized by higher consumption by this
cell line. Acetaldehyde revealed an increased consumption in both pRCC cell lines (Table 2).
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Table 1. List of volatile compounds (VOCs and VCCs) significantly altered between each clear cell renal cell carcinoma (ccRCC; 769-P, 786-O and Caki-1) cell line and
the non-tumoral cell line (HK-2).
Metabolite
769-P (n = 13) vs. HK-2 (n = 12) 786-O (n = 14) vs. HK-2 (n = 12) Caki-1 (n = 11) vs. HK-2 (n = 12)
ES ± SE p-Value a AUC ES ± SE p-Value a AUC ES ± SE p-Value a AUC
Alcohols
2-Ethylhexanol b, L2, * ↑1.42 ± 0.86 E 1.26 × 10−3 0.885 ↑0.94 ± 0.79 E 4.88 × 10−2 0.738 ↑2.39 ± 1.05 E 6.21 × 10−4 0.955
2,6-Dimethyl-7-octen-2-ol b, L2 ↓−1.79 ± 0.94 C 2.02 × 10−3 0.916
Cyclohexanol b, L2 ↓−1.29 ± 0.82 C 8.06 × 10−3 0.821
Levomenthol b, L2 ↓−0.84 ± 0.79 4.90 × 10−2 0.734 ↓−1.30 ± 0.87 C 2.96 × 10−2 0.818
Alkanes
2-Ethoxy-2-methyl-propane b, L2 ↑1.01 ± 0.80 C 3.00 × 10−2 0.762
Decane b, L2 ↑0.84 ± 0.79 4.90 ×10−2 0.734 ↑1.12 ± 0.81 E 2.23 × 10−2 0.780
Tetradecane c, L2, * ↑3.68 ± 1.25 E 2.90 × 10−7 1.000 ↑2.81 ± 1.07 E 2.90 × 10−7 1.000 ↑1.88 ± 0.94 E 5.61 × 10−4 0.909
Dodecane b, L2 ↓−1.29 ± 0.87 C 2.96 × 10−2 0.811
Alkenes
2,4-Dimethyl-1-heptene b, L2 ↑0.80 ± 0.79 C 3.00 × 10−2 0.769 ↑0.89 ± 0.78 C 2.23 × 10−2 0.780
3-Carene b, L1 ↑2.32 ± 0.99 4.33 × 10−5 0.962 ↑1.84 ± 0.90 2.59 × 10−4 0.940
Aldehydes
4-Methylbenzaldehyde b, L2 ↑2.00 ± 0.94 C 1.60 × 10−4 0.936 ↑1.69 ± 0.88 C 1.10 × 10−3 0.899
Benzaldehyde b, L1 ↓−1.59 ± 0.86 C 2.74 × 10−3 0.863
3-Methylbenzaldehyde c, L2 ↑1.75 ± 0.89 E 2.34 × 10−5 0.946 ↑2.03 ± 0.93 E 9.32 × 10−6 0.959
Acetaldehyde c, L1 ↓−10.93 ± 3.06 C 2.90 × 10−7 1.000 ↓−4.48 ± 1.43 C 2.90 × 10−7 1.000 ↓−4.77 ± 1.55 C 5.18 × 10−6 0.992
Formaldehyde c, L2 ↑3.34 ± 1.18 C 2.90 × 10−7 1.000 ↑2.58 ± 1.02 C 2.90 × 10−7 1.000 ↑3.13 ± 1.18 C 5.18 × 10−6 1.000
Decanal b, L1, * ↓−1.72 ± 0.90 C 1.61 × 10−3 0.872 ↓−1.87 ± 0.90 C 3.00 × 10−3 0.857
Benzene Derivatives
Ethylbenzene b, L2 ↑1.46 ± 0.86 3.58 × 10−4 0.917 ↑1.00 ± 0.79 E 2.42 × 10−3 0.875
Styrene b, L2, * ↑1.32 ± 0.84 E 1.61 × 10−3 0.871
Xylene b, L2 ↑1.61 ± 0.88 E 4.33 × 10−5 0.962 ↑1.11 ± 0.81 E 6.27 × 10−4 0.917
Ketones
Acetophenone b, L2 ↓− 0.96 ± 0.80C 4.31 × 10−2 0.750
Cyclohexanone b, L2, * ↓− 3.29 ± 1.19 C 2.88 × 10−6 1.000 ↓−1.53 ± 0.85 C 2.74 × 10−3 0.863 ↓−1.54 ± 0.91 C 6.04 × 10−3 0.879
Acetone c, L2 ↑2.12 ± 0.94 E 5.63 × 10−5 0.929 ↑2.22 ± 0.96 E 7.25 × 10−6 0.964 ↑1.33 ± 0.86 E 6.56 × 10−3 0.833
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Table 1. Cont.
Metabolite
769-P (n = 13) vs. HK-2 (n = 12) 786-O (n = 14) vs. HK-2 (n = 12) Caki-1 (n = 11) vs. HK-2 (n = 12)
ES ± SE p-Value a AUC ES ± SE p-Value a AUC ES ± SE p-Value a AUC
Unknowns
Un (RT 8.40, m/z 69) b, L4 ↑1.44 ± 0.86 C 1.43 × 10−2 0.801 ↑1.53 ± 0.85 C 3.31 × 10−3 0.851
Un (RT 10.18, m/z 58) c, L4 ↑3.64 ± 1.24 E 2.90 × 10−7 1.000 ↑3.07 ± 1.12 E 2.90 × 10−7 1.000 ↑2.04 ± 0.97 E 5.18 × 10−6 0.992
Un (RT 12.82. m/z 69) b, L4 ↑0.98 ± 0.79 2.40 × 10−2 0.774
Un (RT 16.64, m/z 61) b, L4 ↓− 4.16 ± 1.38 2.88 × 10−6 1.000 ↓−4.39 ± 1.41 E 3.73 × 10−6 1.000
ES: Effect size, SE: standard error, AUC: area under the curve. ES and SE were determined as described in reference Berben et al. (2012) [29]. a False discovery rate adjusted p-value;
b, c Compounds detected through VOCs and VCCs analytical methods, respectively. ↑ and ↓: volatile compound found increased and decreased, respectively, in the extracellular medium
of RCC compared with the non-tumoral cell line. E, C Metabolites excreted and consumed, respectively, when compared with blanks. No indication was added when the levels of the
metabolites in tumoral cell lines were similar to that of blanks. L1 Identified metabolites (GC–MS analysis of the metabolite of interest and a chemical reference standard under identical
analytical conditions within the same laboratory).L2 Putatively annotated compounds (spectral MS similarity with the NIST database).L4 Unknown compounds. * Metabolites previously
reported as potential biomarkers of RCC in urine [27].
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Table 2. List of volatile compounds (VOCs and VCCs) significantly altered between papillary renal cell
carcinoma (pRCC; Caki-2 and ACHN) cell line and the non-tumoral cell line (HK-2).
Metabolite
Caki-2 (n = 12) vs. HK-2 (n = 12) ACHN (n = 12) vs. HK-2 (n = 12)
ES ± SE p-Value a AUC ES ± SE p-Value a AUC
Alcohols
2-Ethylhexanol b, L2, * ↑2.51 ± 1.05 E 2.22 × 10−5 0.972 ↑4.29 ± 1.44 E 7.40 × 10−6 1.000
Cyclohexanol b, L2 ↑1.45 ± 0.87 E 2.87 × 10−3 0.868
Alkanes
Tetradecane c, L2, * ↑3.15 ± 1.18 E 8.63 × 10−7 1.000 ↑2.50 ± 1.05 E 1.73 × 10−6 1.000
Aldehydes
4-Methylbenzaldehyde b, L2 ↓−1.84 ± 0.93 C 4.78 × 10−3 0.875
3-Methylbenzaldehyde c, L2 ↑0.81 ± 0.81 C 1.21 × 10−2 0.799
Acetaldehyde c, L1 ↓−9.59 ± 2.82 C 8.63 × 10−7 1.000 ↓−10.95 ± 3.19 C 1.73 × 10−6 1.000
Formaldehyde c, L2 ↑4.39 ± 1.46C 8.63 × 10−7 1.000 ↑2.34 ± 1.02 C 7.25 × 10−6 0.979
Ketones
2-Pentadecanone b, L1 ↓−2.64 ± 1.07 9.86 × 10−6 0.986
Acetophenone b, L2 ↓−4.85 ± 1.57 C 3.70 × 10−6 1.000
Cyclohexanone b, L2, * ↓−7.09 ± 2.15 C 3.70 × 10−6 1.000 ↓−1.40 ± 0.87 C 4.78 × 10−3 0.868
Acetone c, L2 ↑4.63 ± 1.52 E 8.63 × 10−6 1.000 ↑2.89 ± 1.13 E 1.04 × 10−5 0.972
Unknowns
Un (RT 9.80, m/z 59) b, L4 ↑1.55 ± 0.89 C 3.05 × 10−3 0.861
Un (RT 10.18, m/z 58) c, L4 ↑4.65 ± 1.52 E 8.63 × 10−7 1.000 ↑3.38 ± 1.23 E 1.73 × 10−6 1.000
Un (RT 12.82. m/z 69) b, L4 ↓−0.99 ± 0.82 C 2.47 × 10−6 0.785
Un (RT 16.64, m/z 61) b, L4 ↓−1.23 ± 0.85 E 1.13 × 10−2 0.833
ES: effect size, SE: standard error, AUC: area under the curve. ES and SE were determined as described in reference
Berben et al. (2012) [29]. a False discovery rate adjusted p-value; b, c Compounds detected through VOCs and
VCCs analytical methods, respectively. ↑ and ↓: volatile compound found increased and decreased, respectively,
in the extracellular medium of RCC compared with non-tumoral cell line. E, C Metabolites excreted and consumed,
respectively, when compared with blanks. No indication was added when the levels of the metabolites in tumoral
cell lines were similar to that of blanks. L1 Identified metabolites (GC–MS analysis of the metabolite of interest
and a chemical reference standard under identical analytical conditions within the same laboratory). L2 Putatively
annotated compounds (spectral MS similarity with the NIST database). L4 Unknown compounds. * Metabolites
previously reported as potential biomarkers of RCC in urine [27].
2.2. Volatile Exometabolome Signature of Metastatic versus Non-Metastatic RCC Cell Lines and ccRCC versus
pRCC Cell Lines
To investigate the volatile exometabolome signature of RCC cell lines with different metastatic
potential, the same strategy was applied to compare the extracellular medium of metastatic and
non-metastatic RCC cell lines (Figure 4). A good separation was obtained for metastatic vs.
non-metastatic ccRCC cells in VOCs analysis (Q2 > 0.7; Figure 4a), whereas a poor separation
(Q2 = 0.211) was observed in VCCs (Figure 4c). For pRCC, a good separation with high predictive
power (Q2 > 0.9) was observed in both analytical methodologies (Figure 4b,d).
The volatile exometabolome signature of metastatic ccRCC cell lines unveiled statistically
significant alterations in the levels of 15 compounds when compared with non-metastatic cell
lines (Table 3). For pRCC, 17 compounds were found significantly altered between metastatic
and non-metastatic cells. Interestingly, most of these alterations were specific of the RCC histological
subtype with only a decrease in the levels of decane, dodecane and 4-methylbenzaldehyde found in
common for ccRCC and pRCC. In general, metastatic ccRCC cell lines mostly showed dysregulations
in the levels of alkanes and alkenes (decreased and increased) and benzene derivatives (decreased)
when compared with non-metastatic cells, while metastatic pRCC cell lines mostly showed alterations
in the levels of aldehydes (decreased) and ketones (decreased and increased).
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Figure 3












































Figure 3. Heatmaps illustrating the mean levels (normalized peak areas) of metabolites changing in
ccRCC and pRCC cell lines when compared with the non-tumor cell line (HK-2). The levels of those
compounds in blanks (culture medium without cells) are also represented to aid in the interpretation of
the results in terms of excretion and consumption. Rows correspond to the mean normalized peak area
of each metabolite, while the columns represent each sample group.
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Figure 4
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Figure 4. Partial least squares-discriminant analysis (PLS-DA) scores scatter plots obtained for the
HS-SPME/GC–MS chromatogram data of (A) VOCs and (B) VCCs of culture media of the metastatic
cell lines vs. non-metastatic cell lines of each RCC histological subtype. (a,c) metastatic ccRCC (Caki-1,
red, n = 11) vs. non-metastatic ccRCC (769-P and 786-O, dark blue, n = 27) and (b,d) metastatic pRCC
(ACHN, green, n = 12) vs. non-metastatic pRCC (Caki-2, orange, n = 12).
Finally, the comparison of the volatile exometabolome between ccRCC and pRCC unveiled poor
separation in the PLS-DA models of VOCs and VCCs analysis (Figure S3). In the PLS-DA model
of VOCs (Figure S3A), the extracellular media of the Caki-1 cell line was wrongly classified in LV1
positive. Nonetheless, the model showed high predictive power and some statistically significant
alterations between ccRCC and pRCC were disclosed, namely in the levels of 2,4-dimethyl-1-heptene,
3-carene, 4-methylbenzaldehyde, 4-methylheptane and an unknown compound (Un RT 8.40 m/z 69;
Table 3).
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Table 3. List of volatile compounds (VOCs and VCCs) significantly altered between metastatic cell lines compared with non-metastatic cell lines and between RCC
histological subtype (ccRCC and pRCC).
Metabolite
Metastatic ccRCC (n = 11) vs.
Non-Metastatic ccRCC (n = 27)
Metastatic pRCC (n = 12) vs.
Non-Metastatic pRCC (n = 12) ccRCC (n = 38) vs. pRCC (n = 24)
ES ± SE p-Value a AUC ES ± SE p-Value a AUC ES ± SE p-Value a AUC
Alcohols
2-Ethylhexanol b, L2 ↑1.20 ± 0.84 E 1.19 × 10−2 0.828 ↓−0.80 ± 0.52 E 1.88 × 10−3 0.730
Cyclohexanol b, L2 ↑1.83 ± 0.80 E 1.71 × 10−4 0.882 ↓−2.61 ± 1.07 7.40 × 10−6 0.993 ↑1.15 ± 0.54 C 2.04 × 10−5 0.813
Alkanes
2-Ethoxy-2-methyl-propane b, L2 ↓−0.99 ± 0.72 C 7.42 × 10−3 0.781 ↑0.95 ± 0.53 1.13 × 10−4 0.763
Decane b, L2 ↓−2.54 ± 0.89 C 1.05 × 10−7 0.989 ↓−0.96 ± 0.82 C 1.67 × 10−2 0.806 ↓−0.98 ± 0.53 2.89 × 10−4 0.728
Dodecane b, L2 ↓−2.33 ± 0.86 1.35 × 10−6 0.959 ↓−1.28 ± 0.85 1.81 × 10−2 0.799 ↑1.03 ± 0.54 9.68 × 10−5 0.782
4-Methylheptane b, L2 ↓−1.40 ± 0.75 C 2.60 × 10−4 0.872 ↑1.28 ± 0.55 C 1.31 × 10−6 0.839
Tetradecane c, L2 ↓−1.64 ± 0.90 E 5.78 × 10−4 0.896
Alkenes
2,4-Dimethyl-1-heptene b, L2 ↓−1.60 ± 0.77 C 5.02 × 10−5 0.906 ↑1.29 ± 0.55 C 1.31 × 10−6 0.842
3-Carene b, L1 ↓−2.29 ± 0.86 C 2.99 × 10−8 1.000 ↑1.36 ± 0.56 6.99 × 10−7 0.850
Aldehydes
4-Methylbenzaldehyde b, L2 ↓−2.26 ±0.85 C 1.89 × 10−7 0.983 ↓−1.23 ± 0.85 C 2.79 × 10−2 0.778 ↑1.28 ± 0.55 C 2.22 × 10−6 0.827
3-Methylbenzaldehyde c, L2 ↓−0.97 ± 0.82 C 3.84 × 10−4 0.910
Acetaldehyde c, L1 ↓−1.90 ± 0.94 C 3.84 × 10−4 0.917
Formaldehyde c, L2 ↓−1.29 ± 0.85 C 5.56 × 10−3 0.826
Decanal b, L1 ↑2.58 ± 0.90 E 7.25 × 10−7 0.969 ↓−1.07 ± 0.83 E 1.13 ×10−2 0.833 ↑0.54 ± 0.51 E 3.29 × 10−2 0.654
Benzene Derivatives
Styrene b, L2 ↓−1.46 ± 0.76 6.20 × 10−4 0.852
Xylene b, L2 ↓−0.67 ± 0.70 E 3.38 × 10−3 0.808
Ethylbenzene b, L2 ↓−0.51± 0.70 C 7.12 × 10−3 0.784
Ketones
2-Pentadecanone b, L1 ↑2.80 ± 1.11 E 1.11 × 10−5 0.986 ↑0.84 ± 0.53 E 8.89 × 10−4 0.734
4-Methyl-2-hexanone b, L2 ↑0.97 ± 0.53 9.68 × 10−5 0.768
Acetone c, L2 ↓−1.97 ± 0.95 E 3.84 × 10−4 0.910
Acetophenone b, L2 ↑5.83 ± 1.82 C 5.55 × 10−6 1.000 ↓−1.40 ± 0.56 C 2.03 × 10−4 0.761
Cyclohexanone b, L2 ↑8.14 ± 2.44 C 7.40 × 10−6 1.000
Unknowns
Un (RT 8.40, m/z 69) b, L4 ↓−2.02 ± 0.82 C 2.86 × 10−6 0.949 ↓−1.31 ± 0.55 E 6.89 × 10−6 0.795
Un (RT 9.45 m/z 71) b, L4 ↑1.79 ± 0.92 1.56 × 10−2 0.813
Un (RT 9.80, m/z 59) b, L4 ↓−1.79 ± 0.92 4.33 × 10−4 0.924
Un (RT 10.18, m/z 58) c, L4 ↓−1.69 ± 0.91 E 3.84 × 10−4 0.917
Un (RT 12.82. m/z 69) b, L4 ↑1.70 ± 0.79 C 2.00 × 10−5 0.918
Un (RT 16.64, m/z 61) b, L4 ↑3.58 ± 1.06 E 8.00 × 10−7 0.966 ↑1.40 ± 0.56 C 6.99 × 10−7 0.844
ES: effect size, SE: standard error, AUC: area under the curve. ES and SE determined as described in reference Berben et al. (2012) [29]. a False discovery rate adjusted p-value;
b, c Compounds detected through VOCs and VCCs analytical methods, respectively. ↑ and ↓: Volatile compound found increased and decreased, respectively, in the extracellular medium
of metastatic cell lines compared with non-metastatic cell lines and between RCC histological subtype (ccRCC and pRCC). E, C Metabolites excreted and consumed, respectively, when
compared with blanks. No indication was added when the levels of the metabolites in tumoral cell lines were similar to that of blanks. L1 Identified metabolites (GC–MS analysis of the
metabolite of interest and a chemical reference standard under identical analytical conditions within the same laboratory). L2 Putatively annotated compounds (spectral MS similarity with
the NIST database). L4 Unknown compounds.
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3. Discussion
The profiling of volatile compounds present in the culture medium (exometabolome) unveiled
important alterations associated with the excretion and consumption of nutrients by RCC cells lines
when compared with a non-tumor cell line. In addition, different RCC histological subtypes (ccRCC and
pRCC), as well as different stages of the disease (metastatic and non-metastatic) disclosed characteristic
exometabolome signatures. These metabolic alterations may constitute a panel of potential biomarkers
yet to be investigated in urine from RCC patients, compared with cancer-free individuals. Common to
all cancer cell lines under study, we found increased levels of 2-ethylhexanol, tetradecane, formaldehyde,
acetone and an unknown compound (Un RT 10.18 m/z 58), and decreased levels of acetaldehyde and
cyclohexanone. These results suggest that different histological RCC subtypes have, at least in part,
a common regulatory mechanism that affects the metabolic pathways in which these compounds
are intermediates.
In a general way, RCC cell lines present high levels of hydrocarbons (alkanes and alkenes) in
the extracellular medium. The main mechanism that affects the production of hydrocarbons is the
oxidative stress, since the production of these volatile metabolites is mainly due to the induction of
ROS-mediated polyunsaturated fatty acid peroxidation [30]. In fact, some studies have already shown
elevated ROS levels in RCC [31,32] and have also provided evidence that lipid peroxidation is an
important mechanism in renal carcinogenesis [33,34].
Another major change observed in this study was a significant increase of some alcohols (namely
2-ethylhexanol) in RCC cell lines when compared to the non-tumorigenic cell line. These results can be
explained by a possible up-regulation of cytochrome P450 (CYP450) enzymes, which can hydroxylate
several volatiles formed during ROS-mediated lipid peroxidation, leading to the production of the
corresponding alcohols [30]. This theory is supported by some studies [33,35,36] whose results
demonstrated that some CYP isoforms (such as CYP1B1, CYP1A1, CYP2C19, CYP2D6, CYP2E1,
CYP3A4 or CYP3A5) are altered in RCC patients. Furthermore, 2-ethylhexanol has already been
found increased in preoperative vs. postoperative urine samples from RCC patients [27], indicating
that it may be considered a potential translatable biomarker for non-invasive measurement in urine.
However, 2-ethylhexanol has also been reported as a potential urinary biomarker of lung [37] and
prostate [38] cancers, which indicates a lack of specificity towards RCC. Nevertheless, this biomarker
can be combined with others to define a robust panel of biomarkers for early diagnosis of RCC.
In addition, our metabolomic results also showed that most of the aldehydes (e.g.,
4-methylbenzaldehyde, 3-methylbenzaldehyde and formaldehyde) were significantly increased in
RCC cell lines. Increased levels of aldehydes may derive from different mechanisms including a direct
origin in the reduction of hydroperoxides by CYP450 or from the conversion of some alcohols to their
corresponding aldehydes mediated by alcohol dehydrogenases (ADHs) [30]. Since the amount of some
lipids in cancer cells membranes is greater than in normal cells, it can be assumed that the increase
in aldehyde levels in RCC cell lines may be linked to changes in the membrane lipid composition
subsequent to increased oxidative stress [30–32]. Furthermore, it is also known that RCC cells have a
significantly higher activity of total ADH and ADH class I that is exacerbated in patients with a more
advanced stage [39,40], meaning that tumoral cells have an increased ability to produce aldehydes,
which can intensify carcinogenesis. In agreement, a significant enhancement of aldehydes has been
previously shown in urine from RCC patients compared to healthy controls [27].
Remarkably, acetaldehyde, another well-known aldehyde, appears significantly decreased in
all RCC cell lines when compared to the non-tumorigenic cell line. This finding is opposite to what
would be expected based on aforementioned higher activity of ADH in renal cancer cells. The ability of
acetaldehyde to bind to DNA and cellular proteins to form adducts may explain the results verified in
the exometabolome [40]. Moreover, acetaldehyde can lead to activation of proto-oncogenes, inactivation
of tumor suppressor genes in replicating cells and inhibition of many important enzymes of DNA
synthesis pathways, playing an important role in carcinogenesis [40]. Further studies are needed to
explore whether RCC cells possess/induce detoxifying mechanisms for this toxic and reactive aldehyde.
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Ketones were also found altered in the exometabolome of RCC cells compared with the
non-tumor cell line, with special emphasis for acetone whose levels are significantly increased.
Several studies [15,23,41] have associated this class of volatile compounds with altered pathways in
cancer, namely the propensity of tumor cells to favor their metabolism via glycolysis (Warburg effect)
with a consequent increase in lactate secretion. These will lead to an accumulation of acetyl-CoA,
which in turn results in an increased production of ketone bodies, namely acetone [30].
In contrast, cyclohexanone was found decreased in the exometabolome of all RCC cells. Of note,
this finding is not in agreement with the previous study by Wang et al. [27] where they showed
significantly higher levels of cyclohexanone in preoperative urines from RCC patients. Although these
contradictory results may be a result of sources of residual variation as diet, medication use, gender, age
and comorbidities, among others, which may affect urine, further studies should be carried out in the
future. Noticeably, this volatile compound is highly consumed by the pRCC cell line Caki-2 compared
to other cancer cell lines. Caki-2 revealed a different profile since the levels of 2-pentadecanone and
an unknown compound (Un RT 9.80, m/z 59) were found significantly altered only in this pRCC cell
line. Contrary to other RCC histological subtypes, ccRCC and pRCC arise from adjacent parts of
the proximal tubule [42], which may justify the poor discrimination found between both subtypes.
Nevertheless, some volatile compounds were found to be discriminative between ccRCC and pRCC
subtypes, mainly belonging to hydrocarbons, aldehydes and ketone classes. Although differences in
the metabolic profile of ccRCC and pRCC subtypes have already been reported in terms of amino
acid and fatty acid metabolism, whose levels were found to be increased in ccRCC [43], thus being
associated with the higher aggressiveness of ccRCC comparing to the pRCC subtype [42,44], our study
reports for the first time differences in the volatile exometabolome of these two RCC subtypes.
Regarding the comparison metastatic vs. non-metastatic stage in both the clear cell and the
papillary RCC cell lines, the results suggest a variation of the volatile compounds in a stage-dependent
manner since statistically significant differences in the levels of several metabolites were found.
Curiously, the separation between metastatic and non-metastatic cell lines was more robust in the
pRCC subtype, which justifies the markedly altered profile of the pRCC cell line, Caki-2. These
results are consistent with the findings reported by Schaeffeler et al. [42], which demonstrated that
ccRCC-derived metastases showed similar metabolite levels when compared with primary ccRCC. Our
results revealed common alterations in the levels of several alkanes (decanal, decane and dodecane),
one aldehyde (4-methylbenzaldehyde) and one alcohol (cyclohexanol) in all metastatic cell lines
compared with the non-metastatic. Indeed, several ketones and aldehydes were only found altered in
the pRCC metastatic cell line, ACHN. However, our results disclosed decreased levels of aldehydes
in the metastatic cell lines, which may be used in amino acid synthesis, as proposed by some other
authors [23].
This study demonstrates for the first time, to our knowledge, the potential of volatile compounds
in discriminating RCC cells from nonmalignant cells, according to the histological subtype and tumor
stage. However, the metabolic pathways that lead to VOCs and VCCs production are not yet clearly
understood, hindering an accurate interpretation of the results. Nevertheless, our findings support the
hypothesis that altered energy production in RCC cells enables them to survive under oxidative stress
conditions and to migrate to other tissues and form metastases [45]. This study also reinforces that
the investigation of the volatile signature of the exometabolome using cancer cell lines can provide
candidate biomarkers with potential to be translatable for urine of RCC patients, which may ultimately
lead to the development of volatile sensor-based approach for non-invasive diagnosis of RCC.
4. Materials and Methods
4.1. Chemicals
All chemicals were of analytical grade and dissolved in deionized water unless otherwise indicated.
RPMI-1640 medium, sodium chloride (NaCl, ≥ 99.5%), O-(2,3,4,5,6-pentafluorobenzyl) hydroxylamine
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(PFBHA, ≥ 99%) and thymol (≥ 98.5%) were obtained from Sigma-Aldrich (St. Louis, Missouri, USA).
The antibiotic mixture penicillin/streptomycin (10.000 U/mL/10.000 mg/mL), heat-inactivated fetal
bovine serum (FBS) and trypsin-EDTA (0.25%) were purchased from GIBCO Invitrogen (Barcelona,
Spain). Hydrochloric acid (HCl) and sodium hydrogencarbonate were obtained from Merck
(Darmstadt, Germany).
4.2. Cell lines and Culture Conditions
Five human RCC immortalized cell lines (769-P, 786-O, ACHN, Caki-1 and Caki-2) and one
non-tumorigenic renal cell line (HK-2) were purchased from the American Type Culture Collection
(ATCC; Manassas, VA, USA) and their characteristics are summarized in Table S1. The selection of
tumorigenic cell lines was carried out to allow the study of the most common RCC subtypes (ccRCC
and pRCC) at different disease stages. Thus, 769-P and 786-O are recognized as primary ccRCC
while Caki-1 is a metastatic ccRCC cell line [46]. Furthermore, and despite some controversies in
histological classification, Caki-2 has been recognized as a primary pRCC cell line expressing papillary
characteristics and ACHN is considered a metastatic pRCC cell line [46]. HK-2 is an immortalized
proximal tubule cell line derived from normal human kidney [47]. All cell lines were grown in
RPMI-1640 supplemented with 10% of FBS and 1% penicillin/streptomycin and incubated at 37 ◦C and
5% CO2. All cell lines were routinely tested for Mycoplasma spp. contamination (PCR Mycoplasma
Detection Set, TaKaRa).
For each cell line, two different cell stock vials were grown in parallel and the experiments carried
out up to 7 consecutive passages in plastic T25 culture flasks, after an adaptation stage of at least three
passages for all cell lines. After 24 h, a confluence of 50%–60% was observed, the culture medium was
discarded and replaced with 7 mL of fresh culture medium (which was prepared in enough amount to
maintain the same composition in all collected flasks, thus reducing possible bias). The culture flasks
were maintained in the incubator for another 48 h reaching near confluence, together with blanks (T25
culture flasks with the same culture medium but without cells). After 48 h, the extracellular medium
from each culture flask with cells and blanks was collected and centrifuged (5 min, 2000g, 4 ◦C). Then,
the supernatant was divided into two 2.5 mL aliquots and immediately stored at −80 ◦C until analysis.
A pool of all samples and blanks, called quality control (QCs), was also prepared under the same
collection and storage conditions.
4.3. Sample Preparation and Volatile Extraction by HS-SPME
Sample preparation was performed as described in previous studies published by our
group [21,24,28,48]. Briefly, stored samples were first thawed slowly on ice to minimize the loss
of volatiles. For VOCs analysis, 2 mL of each extracellular culture medium was transferred to a 10 mL
glass vial with 30 µL of the internal standard (thymol, 2 mg/L) and 0.43 g of NaCl (salting out effect).
Then, VOCs were extracted through HS-SPME using a divinylbenzene/carboxen/polydimethylsiloxane
(DVB/CAR/PDMS) fiber with an incubation time of 11 min and extraction of 30 min at
44 ◦C, under continuous stirring (250 rpm) [21,24,48]. For VCCs analysis, 2 mL of each
culture medium was placed into a 10 mL glass vial with 47 µL of the derivatizing agent
(O-(2,3,4,5,6-pentafluorobenzyl) hydroxylamine, 40 g/L) and the compounds were extracted using a
polydimethylsiloxane/divinylbenzene (PDMS/DVB) fiber with an incubation time of 6 min at 62 ◦C
and extraction using the same temperature during 51 min, under continuous stirring (250 rpm) [28,48].
All samples were randomly injected, and the QCs were injected at the same conditions, on every 6
samples, to evaluate the reproducibility in both analyses.
4.4. GC–MS Analysis: Equipment and Conditions
VOCs detection was accomplished using a 436-GC system (Bruker Daltonics, Fremont, CA)
coupled to a SCION Single Quadrupole (SQ) mass detector and a Bruker Daltonics MS workstation
software (version 8.2). A fused silica capillary column Rxi-5Sil MS (30 m × 0.25 mm × 0.25 µm; RESTEK
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Corporation, U.S., Bellefonte, Pennsylvania) was used and helium C-60 (Gasin, Portugal) was the
carrier gas (flow rate 1 mL/min). The oven temperature was fixed at 40 ◦C for 1 min, increasing to 250 ◦C
(rate 5 ◦C/min), held for 5 min, followed by increasing to 300 ◦C (rate 5 ◦C/min) and held for 1 min.
The MS detector was operated in electron impact mode (70 eV) at 260 ◦C, the transfer line temperature
was 250 ◦C and the manifold temperature was 40 ◦C. Data acquisition was performed in full scan
mode with a mass range between 40 and 350 m/z at a scan rate of 6 scans/s. VCCs were analyzed
using a 436-GC system (Bruker Daltonics, Fremont, CA) coupled to a EVOQ Triple Quadrupole (TQ)
mass detector and a Bruker MS workstation software version 8.2. The column, carrier gas and oven
temperature conditions were the same described above for VOCs analysis. The MS detector was
operated in the electron impact mode (70 eV) at 270 ◦C, the temperature of transfer line and manifold
were 260 ◦C and 40 ◦C, respectively. Data acquisition was performed in the full scan mode considering
a 50–600 m/z mass range.
4.5. Compound Identification and GC–MS Data Pre-Processing
Compounds detected in both VOCs and VCCs analytical methodologies were identified by
comparison of the MS fragmentation with the mass spectra present in the National Institute of
Standards and Technology (NIST 14) database and by comparing the experimental Kovats retention
index (RI) with literature. When possible, the identification was confirmed by comparison of the
retention time and MS spectra of the samples with the commercially available standard compounds
analyzed using the same conditions.
Before statistical analysis, the data obtained from GC–MS were converted into a manageable
format (netcdf) and preprocessed using MZmine 2.53 [49]. The preprocessing steps consisted of
filtering, peak detection, chromatogram deconvolution and alignment. The parameters used for
preprocessing of VOCs profile were: RT range 2–32 minutes; m/z range 50–250; MS data noise level
1 × 104; m/z tolerance 0.3; chromatogram baseline level 5 × 104 and peak duration range 0.05–1 min.
For VCCs analysis, the parameters used were RT range 9–45 minutes; m/z range 50–500; MS data noise
level 1 × 104; m/z tolerance 0.3; chromatogram baseline level 1 × 104; peak duration range 0.03–0.2 min.
GC contaminants from the chromatographic column or fiber (among others) were manually removed
from the final data matrix.
4.6. Statistical Analysis
The statistical analysis pipeline used for VOCs and VCCs final matrix was the same. First,
data were normalized by the total area (TA) of the chromatogram and scaled to Pareto. Then, PCA
(unsupervised analysis) was applied to detect trends, outliers and to evaluate the distribution of the
QCs, followed by PLS-DA (supervised analysis) to discriminate classes and to identify the specific
metabolic signature of each cell line, in SIMCA 15.0.2 (Umetrics Umea, Sweden). A default sevenfold
internal cross-validation and permutation testing were used to confirm the robustness of PLS-DA
models. All volatile compounds with VIP (variable importance in the projection) higher than one were
considered important for group discrimination and were subsequently submitted to the Mann–Whitney
test. The false discovery rate (FDR) method was used to adjust p-values for multiple comparison using
the MetaboAnalyst 4.0 [50], and compounds with p-value < 0.05 were considered statistically significant.
In addition, the AUC (area under the curve) was computed for each discriminant compound using the
same analytical platform. The effect size and the standard error were also computed as described by
Berben et al. [29]. Finally, the average normalized area of each statistically significant compound in
each sample group was represented in a heatmap in MetaboAnalyst 4.0.
5. Conclusions
In this study, we used an in vitro metabolomics approach to obtain the volatile signatures of RCC
cells with distinct histological subtypes and stages. The results showed that alterations in the volatile
profile are capable of discriminating RCC from non-tumorigenic renal cells. This unique volatile
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profile of RCC cells can be useful to unveil promising noninvasive biomarkers for early diagnosis
in more complex biological matrices, such as urine. A multi-biomarker panel can provide a more
robust and accurate tool for RCC diagnosis than the use of only one metabolite as a biomarker. Indeed,
2-ethylhexanol, tetradecane, formaldehyde, acetone, cyclohexanone and acetaldehyde were able to
discriminate RCC cell lines from the non-tumor cell line and may constitute a potential panel of
candidate biomarkers for RCC diagnosis. This study also demonstrated that the volatile profile of
metastatic cell lines markedly differed from the non-metastatic in each RCC subtype, indicating some
promising biomarkers applicable to the categorization of tumor stage, pending further investigation
and validation.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/5/174/s1,
Table S1: Characteristics of RCC cell lines (769-P, 786-O, Caki-1, Caki-2 and ACHN) and non-tumoral cell
line (HK-2); Figure S1: HS-SPME-GC–MS chromatograms of (A) VOCs and (B) VCCs of QC culture medium.
1: 2-ethyl-hexanol; 2: acetophenone; 3: dodecane; 4: decanal; 5: dodecanal; 6: 2-pentadecanone; 7: formaldehyde;
8: acetaldehyde; 9: acetone; 10: tetradecane; 11: 2-octanone; 12: 3-methyl-benzaldehyde; Figure S2: PCA scores
scatter plots obtained for the HS-SPME/GC–MS chromatogram data of (A) VOCs and (B) VCCs of culture media of
QCs (dark blue, n = 15) vs. all cell lines and blanks (green, n = 88); Figure S3: PLS-DA scores scatter plots obtained
for the HS-SPME/GC–MS chromatogram data of (A) VOCs and (B) VCCs of culture media of ccRCC cell lines
(769-P, 786-O and Caki-1, light blue, n = 38) vs. pRCC cell lines (Caki-2 and ACHN, red, n = 24); In vitro RCC
data.xlsx file containing all data obtained in this study.
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